ArticlePloS one2009
Antibody complementarity-determining regions (CDRs): a bridge between adaptive and innate immunity.
Article in PloS one, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 57 citations in OpenAlex.
- Learning the language of protein-protein interactions.Nature communications · 2026Article
- Killer Peptide: an antibody-derived self-assembling peptide bridging antimicrobial and host-defense mechanisms.FEMS microbiology reviews · 2026Review
- T-cell receptor insights: Determinants of Major Histocompatibility Complex class I versus class II recognition.Protein science : a publication of the Protein Society · 2025Article
- Learning the language of protein-protein interactions.bioRxiv : the preprint server for biology · 2025Article
- ParaSurf: a surface-based deep learning approach for paratope-antigen interaction prediction.Bioinformatics (Oxford, England) · 2025Article
- Antibody numbering schemes: advances, comparisons and tools for antibody engineering.Protein engineering, design & selection : PEDS · 2025Review
- Development of the TSR-based computational method to investigate spike and monoclonal antibody interactions.Frontiers in chemistry · 2025Article
- AntiBinder: utilizing bidirectional attention and hybrid encoding for precise antibody-antigen interaction prediction.Briefings in bioinformatics · 2024Article
- Characterization of a Monoclonal Antibody by Native and Denaturing Top-Down Mass Spectrometry.Journal of the American Society for Mass Spectrometry · 2024Article
- Synthetic Antimicrobial Immunomodulatory Peptides: Ongoing Studies and Clinical Trials.Antibiotics (Basel, Switzerland) · 2022Article
- Co-Functionalization of Gold Nanoparticles with C7H2 and HuAL1 Peptides: Enhanced Antimicrobial and Antitumoral Activities.Pharmaceutics · 2022Article
- Immunoglobulin A, an Active Liaison for Host-Microbiota Homeostasis.Microorganisms · 2021Review
- Contribution of the Commensal Microflora to the Immunological Homeostasis and the Importance of Immune-Related Drug Development for Clinical Applications.International journal of molecular sciences · 2021Review
- A Peptide Found in Human Serum, Derived from the C-Terminus of Albumin, Shows Antifungal Activity In Vitro and In Vivo.Microorganisms · 2020Article
- Synthetic Polyclonal-Derived CDR Peptides as an Innovative Strategy in Glaucoma Therapy.Journal of clinical medicine · 2019Article
- Molecular, Biological and Structural Features of VFrontiers in oncology · 2019Article
- Immunomodulatory Protective Effects of Rb9 Cyclic-Peptide in a Metastatic Melanoma Setting and the Involvement of Dendritic Cells.Frontiers in immunology · 2019Article
- Blockade of MIF-CD74 Signalling on Macrophages and Dendritic Cells Restores the Antitumour Immune Response Against Metastatic Melanoma.Frontiers in immunology · 2018Article
- Fungicidal activity of peptides encoded by immunoglobulin genes.Scientific reports · 2017Article
- A Naturally Occurring Antibody Fragment Neutralizes Infectivity of Diverse Infectious Agents.Scientific reports · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundIt has been documented that, independently from the specificity of the native antibody (Ab) for a given antigen (Ag), complementarity determining regions (CDR)-related peptides may display differential antimicrobial, antiviral and antitumor activities. METHODOLOGY/PRINCIPAL
findingsIn this study we demonstrate that a synthetic peptide with sequence identical to V(H)CDR3 of a mouse monoclonal Ab (mAb) specific for difucosyl human blood group A is easily taken up by macrophages with subsequent stimulation of: i) proinflammatory cytokine production; ii) PI3K-Akt pathway and iii) TLR-4 expression. Significantly, V(H)CDR3 exerts therapeutic effect against systemic candidiasis without possessing direct candidacidal properties. CONCLUSIONS/SIGNIFICANCE: These results open a new scenario about the possibility that, beyond the half life of immunoglobulins, Ab fragments may effectively influence the antiinfective cellular immune response in a way reminiscent of regulatory peptides of innate immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.